Galafold Capsule
NDC Package 71904-100-01
Package Information
Galafold (migalastat hydrochloride) capsules is gALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data [see Dosage and Administration (2.1) and Clinical Pharmacology (12.1)].This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate [see Clinical Studies (14)]. This formulation utilizes a capsule delivery system. Marketed by Amicus Therapeutics Us, Llc, this product is identified by NDC 71904-100 and is authorized under FDA application NDA208623.
Identification & Billing
- RxCUI: 2054257 - migALAstat 123 MG Oral Capsule
- RxCUI: 2054257 - migalastat 123 MG Oral Capsule
- RxCUI: 2054257 - migalastat 123 MG (as migalastat HCl 150 MG) Oral Capsule
- RxCUI: 2054263 - Galafold 123 MG Oral Capsule
- RxCUI: 2054263 - migalastat 123 MG Oral Capsule [Galafold]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71904 - Amicus Therapeutics Us, Llc
- 71904-100 - Galafold
- 71904-100-01 - 14 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK
- 71904-100 - Galafold
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71904-100-01 identifies a specific commercial package of 14 blister pack in 1 carton / 1 capsule in 1 blister pack of Galafold, a human prescription drug labeled by Amicus Therapeutics Us, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 14 billable units per package. This capsule is formulated for oral use and contains migalastat hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amicus Therapeutics Us, Llc on August 10, 2018. The current certification is valid through December 31, 2027.
How is this Amicus Therapeutics Us, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71904010001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 14 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.